CANF
USDCan-Fite Biopharma Ltd Sponsored ADR (Israel)
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$1.165
Máximo
$1.170
Mínimo
$1.130
Volume
0.00M
Fundamentos da empresa
Capitalização de mercado
15.8M
Setor
Biotecnologia
País
Israel
Estatísticas de negociação
Volume médio
0.29M
Bolsa de valores
ASE
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma with a Buy and maintains $10 price target.
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
Ramat Gan, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory
Can-Fite Reports 2024 Financial Results and Clinical Update
RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and
Ações relacionadas
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.